Xiaojin An focuses her practice on obtaining and defending intellectual property rights for clients in the fields of pharmaceuticals, biotechnology, and diagnostics. She has extensive experience in antibodies, peptides, vaccines, stem cells, immune therapies, diagnostic methods, gene editing, and personalized medicine.
Xiaojin represents clients in patent proceedings before the European Patent Office, including drafting, prosecution, opposition, and appeal. She also has experience in national invalidity and infringement proceedings. Xiaojin advises clients on opposing and defending patents, freedom-to-operate, patent life cycle management, and supplementary protection certificates (SPCs). In addition to managing global patent portfolios, Xiaojin conducts IP due diligence in connection with merger, acquisition, and license agreements.
Prior to joining Jones Day in 2013, Xiaojin was a postdoctoral fellow at the Swiss Federal Institute of Technology Zurich (ETH), where her research focused on profiling circulating microRNA biomarkers for cancer and identification of metabolic addiction pathways for cancer cell survival. Xiaojin carried out her Ph.D. studies at Harvard Medical School and Peking University. She received an outstanding doctoral dissertation award for her work on angiogenesis in cancer and cardiovascular disease, focusing on gene regulation in hypoxic endothelium. Xiaojin has published eight research articles and reviews in peer-reviewed top journals.
- September 25, 2019
Maximizing protection for your key therapeutic product in Europe.
- European Qualifying Examination (2017); Chinese Patent Attorney Qualification (2017); Peking University (Ph.D. in Cell Biology 2011); Beth Israel Deaconess Medical Center/Harvard Medical School (Visiting Research Scholar, 2007-2010); China Agriculture University (B.S. in Biological Sciences 2006)
- European Patent Office (EPO)
- Chinese, English, German (basic knowledge)